Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly stock has advanced more than 200% over the ... commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for ...

Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro ... or is Lilly stock still a buy? Let's find out. So, first let's talk about the Eli Lilly story ...

Notably, Bernstein analysts reaffirmed an “Outperform” rating on Eli Lilly and Company (NYSE:LLY)’s stock with the price ... in the tirzepatide complex (Mounjaro/Zepbound) was caused by ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...